文献速递流行病学与生物统计真实世界研究与卫生经济

一般人群女性宫颈癌筛查、分流与治疗策略的获益、危害与成本效果

Benefits, harms and cost-effectiveness of cervical screening, triage and treatment strategies for women in the general population.
PubMed 文献 · Nat Med · 2023-12-12

为支持世界卫生组织(WHO)消除宫颈癌战略,本研究使用Policy1-Cervix建模平台,在78个低收入和中低收入国家的一般人群女性中评估七种初筛策略。假设覆盖率70%,每5年一次的人乳头瘤病毒(HPV)初筛最有效且最具成本效果,可使宫颈癌年龄标化死亡率降低63-67%。该结果直接支持WHO 2021年更新的宫颈癌筛查指南。

要点

  • 每5年一次HPV初筛可使宫颈癌年龄标化死亡率降低63-67%(假设覆盖率70%)。
  • 治疗前分流(16/18基因分型、细胞学、醋酸目视检查或阴道镜)效果与HPV初筛接近且癌前病变治疗更少。
  • 每3年一次醋酸目视检查或细胞学的效果与成本效果均低于每5年一次HPV筛查。

核心结论

  • 在低收入和中低收入国家,HPV初筛是最有效、最具成本效果和效率的宫颈癌筛查选择。
  • 该研究结果直接支持WHO更新的一般人群女性宫颈癌筛查指南。

研究设计与样本

  • 研究使用已建立的Policy1-Cervix建模平台,评估七种初筛策略。
  • 评估对象为78个低收入和中低收入国家的一般人群女性。

主要发现

  • 假设覆盖率70%,每5年一次的HPV初筛使宫颈癌年龄标化死亡率降低63-67%。
  • 含治疗前分流(16/18基因分型、细胞学、醋酸目视检查或阴道镜)的策略效果与不分流HPV筛查接近,且癌前病变治疗更少。
  • 每3年一次醋酸目视检查或细胞学的效果与成本效果均低于每5年一次HPV筛查。
  • 醋酸目视检查产生的癌前病变治疗数量超过HPV筛查的两倍。

关键数值与推荐

  • WHO更新指南推荐一般人群女性采用HPV初筛,可采取筛查即治疗或筛查-分流-治疗路径,从30岁开始,每5年或每10年筛查一次。

临床怎么用

  • 作者认为,在低收入和中低收入国家,HPV初筛是最有效、最具成本效果和效率的宫颈癌筛查选择。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

In 2020, the World Health Organization (WHO) launched a strategy to eliminate cervical cancer as a public health problem. To support the strategy, the WHO published updated cervical screening guidelines in 2021. To inform this update, we used an established modeling platform, Policy1-Cervix, to evaluate the impact of seven primary screening scenarios across 78 low- and lower-middle-income countries (LMICs) for the general population of women. Assuming 70% coverage, we found that primary human papillomavirus (HPV) screening approaches were the most effective and cost-effective, reducing cervical cancer age-standardized mortality rates by 63-67% when offered every 5 years. Strategies involving triaging women before treatment (with 16/18 genotyping, cytology, visual inspection with acetic acid (VIA) or colposcopy) had close-to-similar effectiveness to HPV screening without triage and fewer pre-cancer treatments. Screening with VIA or cytology every 3 years was less effective and less cost-effective than HPV screening every 5 years. Furthermore, VIA generated more than double the number of pre-cancer treatments compared to HPV. In conclusion, primary HPV screening is the most effective, cost-effective and efficient cervical screening option in LMICs. These findings have directly informed WHO's updated cervical screening guidelines for the general population of women, which recommend primary HPV screening in a screen-and-treat or screen-triage-and-treat approach, starting from age 30 years with screening every 5 years or 10 years.

来源:Nat Med,查看原文。版权归原作者所有。

引用

  1. Simms KT, Keane A, Nguyen DTN, et al. Benefits, harms and cost-effectiveness of cervical screening, triage and treatment strategies for women in the general population. Nat Med. 2023. PMID: 38087115. doi:10.1038/s41591-023-02600-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。